Evidence map›Paper›PMID 25009819›Full record

ArticleBioMed research international2014

HS1,2 Ig enhancer alleles association to AIDS progression in a pediatric cohort infected with a monophyletic HIV-strain.

Carla Montesano, Vincenzo Giambra, Domenico Frezza, Paolo Palma, Eliseo Serone, Guido Castelli Gattinara, Maurizio Mattei, Giorgio Mancino, Vittorio Colizzi, Massimo Amicosante

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Carla MontesanoDepartment of Biology, University of Rome "Tor Vergata," 00133 Rome, Italy.ORCID 0000-0002-9865-6619
Vincenzo GiambraDepartment of Biology, University of Rome "Tor Vergata," 00133 Rome, Italy ; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada V5Z 1L3.ORCID 0000-0003-2607-2080
Domenico FrezzaDepartment of Biology, University of Rome "Tor Vergata," 00133 Rome, Italy.
Paolo PalmaUniversity Department of Pediatrics, DPUO, Unit of Immune and Infectious Diseases, Children's Hospital "Bambino Gesù," 00165 Rome, Italy.
Eliseo SeroneIstituto Mario Negri Sud, 66030 Chieti, Italy.ORCID 0000-0002-4582-9731
Guido Castelli GattinaraInternational Training Unit, Children's Hospital "Bambino Gesù," 00165 Rome, Italy.
Maurizio MatteiDepartment of Biology, University of Rome "Tor Vergata," 00133 Rome, Italy.
Giorgio MancinoSan Pietro Fatebenefratelli Hospital, 00189 Rome, Italy.
Vittorio ColizziDepartment of Biology, University of Rome "Tor Vergata," 00133 Rome, Italy.ORCID 0000-0003-0007-8580
Massimo AmicosanteDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata," 00133 Rome, Italy ; ProxAgen Ltd., 1505 Sofia, Bulgaria.
University of Rome Tor Vergata · ITBambino Gesù Children's Hospital · ITFatebenefratelli Hospital · ITMario Negri Sud Foundation · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alteration in the humoral immune response has been observed during HIV infection. The polymorphisms of enhancer HS1,2, member of the 3(') regulatory region of the Ig heavy chain cluster, may play a role in the variation of the humoral response leading to pathological conditions. To assess the role of the HS1,2 polymorphic variants in the progression of AIDS, the HS1,2-A allelic frequencies were investigated in a cohort of HIV infected pediatric subjects from a nosocomial outbreak with a monophyletic strain of HIV. From a total group of 418 HIV infected children in the outbreak cohort, 42 nonprogressors and 31 progressors without bias due to antiretroviral therapy were evaluated. HS1,2 allele (∗)1 has been associated with nonprogressors (allelic frequency: 51.19% versus 33.87% in progressors, OR 0.5, and P = 0.0437), while allele (∗)2 has been associated with progression (allelic frequency: 48.39% versus 30.95% in nonprogressors, OR 2.1, and P = 0.0393). Further, only subjects carrying allele (∗)2 in absence of allele (∗)1, either in homozygous condition for allele (∗)2 [nonprogressors 2/42 (4.76%), Progressors 7/31 (22.58%), OR 5.8, and P = 0.0315] or in combination with other allelic variants [nonprogressors 7/42 (16.67%), Progressors 13/31 (41.93%), OR 3.61, and P = 0.0321], have been associated with HIV progression to AIDS. In conclusion, while the HS1,2 allele (∗)1 has a protective effect on HIV progression when present, allele (∗)2 is associated with progression toward AIDS when allele (∗)1 is absent.

Indexed as

AllelesHIV-1Acquired Immunodeficiency SyndromeAdolescentChildChild, PreschoolCohort StudiesDisease ProgressionEnhancer Elements, GeneticFemaleHumansImmunity, HumoralImmunoglobulin Heavy ChainsInfantMaleImmunoglobulin Heavy Chains

Identifiers

PMID25009819
PMCPMC4055013
OpenAlexW2144489396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.